New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
08:19 EDTAGN, VRXValeant says 'clear' that Allergan 'will never sit down' with company
Valeant (VRX) says it remains committed to the Allergan (AGN) deal, that it has "a clear path to completion of a transaction" and that the company will "be patient since time is on our side." Valeant plans to launch an exchange offer this week to take its proposal directly to Allergan shareholders and said that Pershing has commenced Delaware litigation to facilitate the solicitation process. Valeant says a hearing on a motion to expedite is scheduled for June 19. Valeant says an application to the court has been made by holders of 10% of Allergan shares to call a meeting to elect replacement directors and that a meeting should be held within "approximately two months" of the application. Information from slides for Valeant Pharmaceuticals "webcast to correct recent misrepresentations."
News For VRX;AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
07:29 EDTVRXValeant selected as lead bidder to acquire Dendreon, Provenge for $296M
Subscribe for More Information
05:20 EDTVRXDendreon reaches agreement for Valeant to serve as 'stalking horse bidder'
Subscribe for More Information
January 26, 2015
17:34 EDTAGNActavis registration statement for Allergan acquisition declared effective
Subscribe for More Information
January 22, 2015
05:57 EDTVRXActavis, Valeant raise prospects of more healthcare deals, Financial Times says
Subscribe for More Information
January 21, 2015
12:30 EDTAGN, VRXGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
07:22 EDTAGNActavis price target raised to $330 from $280 at Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use